RxDoctor Payments Data

Jaclyn Neveu, PA

Medical · Norwich, CTNPI 1669031563

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Medtronic at 53.4% of the total. Reporting peaked in 2022 at $3,933 and has fallen 70.5% since, to $1,161 in 2025. Among medical clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,829in general payments, 2019–2025

Across 109 payments — averaging $71.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Impulse Dynamics (USA) Inc.$1K
  • Boston Scientific$1K
  • Abbott$229
  • E.r. Squibb & Sons, L.L.C.$218
  • Atricure, Inc.$156
  • plus $371 from 6 others

What the payments were for

  • Travel & lodging$4,37056%
  • Food & beverage$3,40944%
  • Education$501%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,829 in reported general payments places this provider in the 90th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$46,979
Medicare patients
191
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$328,218
XareltoRivaroxaban46$59,920
Dofetilide80$23,209
Mexiletine Hcl120$14,447
Metoprolol Succinate305$4,976
Flecainide Acetate42$2,477
Amiodarone Hcl99$1,833
SotalolSotalol Hcl26$770
Metoprolol Tartrate76$580
Diltiazem 24hr Er (Cd)Diltiazem Hcl23$537
Diltiazem Hcl13$247
Carvedilol33$229
Propranolol Hcl14$167
Furosemide38$114
ClopidogrelClopidogrel Bisulfate12$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$135$328,218256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 592 medical providers in Connecticut.

Other medical in Norwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →